Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants who withdrew due to adverse events between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher proportion of participants who withdrew due to adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Treatment success (caries lesion arrest or restoration survival) · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in treatment success compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) compared with placebo (very low certainty).
1 finding from 1 review
Remission (response plus end score 8 or less) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes remission (response plus end score 8 or less) compared with light therapy (very low certainty).
1 finding from 1 review
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
Response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
Fluoxetine showed no clear difference in response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
> 50% reduction in depressive symptoms · people with epilepsy and depression
Paroxetine showed no clear difference in > 50% reduction in depressive symptoms compared with doxepin (moderate certainty).
1 finding from 1 review
Seizure frequency · people with epilepsy and depression
1 finding from 1 review